Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
PHOENIX, Feb. 03, 2016 -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “Company”) today announced that the Company will release its financial results for the fourth quarter and full year 2015 on Tuesday, February 23, 2016, before the U.S. financial markets open.
Following the release of the financial results, Dr. John N. Kapoor, President and Chief Executive Officer, and Darryl S. Baker, Chief Financial Officer, will host a conference call at 10:00 a.m. Eastern Standard Time.
Interested parties may participate in the conference call by dialing (877) 349-4844 (U.S.) or (262) 558-6141 (International), 5-10 minutes prior to the start of the call. A replay will be available shortly after the completion of the call for one week by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (International) and entering conference call ID number 43995357.
A live audio webcast and archive of the call will also be available at www.insysrx.com.
About Insys Therapeutics, Inc.
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets one product, Subsys® (fentanyl sublingual spray). The Company recently submitted a New Drug Application to the U.S. Food and Drug Administration for Syndros® (dronabinol oral solution), a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is developing a pipeline of sublingual sprays, as well as pharmaceutical cannabidiol.
Subsys® and Syndros® are registered trademarks of Insys Therapeutics, Inc.
Contact: Lisa M. Wilson President In-Site Communications, Inc. 212-452-2793
